FDA NasoClear coverage for business development, investment, and market access teams
The FDA has approved NasoClear, marking it as the first nasal spray specifically designed for treating pediatric RSV, providing hope for affected children and their families.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
